Christophe Moreno
Christophe Moreno is an expert in Hepatology at Cliniques Universitaires Saint-Luc (Belgium). As of October 2026, ScienceLeadR ranks Christophe Moreno in the top 1% of experts worldwide for Alcohol-Induced Disorders, MASH and Hepatitis. Christophe Moreno has authored 469 publications, the most recent in 2026, and is an investigator in 43 clinical trials, 5 of them ongoing. SLR score: 1,868 (community average: 125). How the SLR is computed.
LeadR Profile
Hepatology
Subspecialties: Gastroenterology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1999 - 2026
Number : 469
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Limited Added Prognostic Value of Choline PET/CT in Treatment-Naïve Hepatocellular Carcinoma. PMID 42787874 — choline, carcinoma, hepatocellular, neoplasms, positron emission tomography computed tomography, therapeutics | World J Nucl Med | 2026 | 0 |
| Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026. PMID 42613687 — liver diseases, hypertension, carcinoma, hepatocellular, cholangitis, fibrosis, non-alcoholic fatty liver disease, liver, hypertension, portal, therapeutics, hepatitis, peroxisome proliferator-activated receptors | Liver Int | 2026 | 0 |
| Corticosteroids in severe alcohol-related hepatitis: a multicenter randomized clinical trial. PMID 42456804 — mortality, incidence, adrenal cortex hormones, biopsy, aged, hepatitis a, therapeutics, infections, hepatitis, bilirubin | JHEP Rep | 2026 | 0 |
| Assessing Europe's policy readiness to confront the MASLD/MASH public health threat. PMID 42266904 — liver diseases, diabetes mellitus, non-alcoholic fatty liver disease, public health, liver, obesity | Lancet Reg Health Eur | 2026 | 0 |
| Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohort. PMID 42162913 — hepatitis d, fibrosis, hepatitis d, chronic, hepatitis delta virus, hepatitis, chronic, liver, therapeutics, antiviral agents, infections, hepatitis, liver stiffness | JHEP Rep | 2026 | 0 |
Clinical Studies 43
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) 2025-522674-36-00 — liver diseases, liver | Phase 3 | Recruiting | 2026 |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes) NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic | Phase 3 | Recruiting | 2025 |
| Global Research Initiative for Patients Screening on MASH NCT05651724 — diabetes mellitus, hypertension, liver cirrhosis, fibrosis, non-alcoholic fatty liver disease, liver, patient care, obesity, research, fatty liver, metabolic syndrome, diabetes mellitus, type 2 | N/A | Recruiting | 2023 |
| Research Study on Whether Semaglutide Works in People With Non alcoholic Steatohepatitis (NASH) NCT04822181 — liver diseases, skin, non-alcoholic fatty liver disease, liver, alcoholics, research, fatty liver, fatty liver, alcoholic, semaglutide | Phase 3 | Active not recruiting | 2021 |
| COIN B COntrolled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Infections NCT04779970 — hepatitis, chronic, hepatitis a, therapeutics, hepatitis b, hepatitis b, chronic, infections, hepatitis | N/A | Active not recruiting | 2021 |
LeadR Networks
Main global connection map